Dr. Ching Pui has dedicated over four decades at St. Jude Children's Research Hospital to revolutionizing the treatment of pediatric acute lymphoblastic leukemia (ALL), transforming what was once a devastating diagnosis into a largely curable condition. His pioneering work has fundamentally changed how children with leukemia are treated worldwide.
Transformative Research Impact
The cornerstone of Dr. Pui's scientific contributions is the landmark TOTXV study (NCT00137111), conducted from 2000 to 2007. This groundbreaking trial introduced minimal residual disease-directed therapy, pushing survival rates beyond 90% without introducing new drugs. Significantly, the study demonstrated that prophylactic cranial irradiation could be safely eliminated from standard treatment protocols, reducing long-term side effects for survivors.
"Our team developed the inaugural clinical trial employing minimal residual disease–directed therapy, significantly elevating survival rates to surpass the 90% mark [and] dramatically improving outcomes without adding new drugs," Pui explained. This approach has enabled more precise treatment calibration, reducing both overtreatment and undertreatment while minimizing toxicity.
Global Impact and Advocacy
Dr. Pui's influence extends far beyond St. Jude's walls. In 1991, through Project HOPE, he began sharing medical expertise with hospitals in Shanghai, China. His advocacy was instrumental in making ALL one of the first diseases covered by China's national insurance, dramatically improving access to treatment in a region where previously less than 30% of diagnosed children received care.
The establishment of the Partner in HOPE Foundation Limited in Hong Kong in 2003 further expanded access to treatment for underprivileged children with ALL, achieving an impressive 84% survival rate among its initial 155 patients. His continued collaboration with Chinese colleagues culminated in the 2024 opening of the National Children's Medical Center in Shanghai, now the world's largest pediatric cancer center with 500 beds.
Innovation in Treatment Protocols
Recent research led by Dr. Pui continues to advance the field. The CCCG-ALL-2015 trial in China demonstrated excellent outcomes without preventive cranial irradiation, achieving a five-year survival rate of 91%. A subsequent phase 2 trial investigating CD19 and CD22 chimeric antigen receptor T-cell protocols showed remarkable results, with 99% of patients with refractory leukemia achieving complete remission.
Patient-Centered Approach
Despite his numerous scientific achievements, Dr. Pui maintains a deep commitment to patient care. "I admire the resilience of my patients. No matter how sick they are, they amaze me with their ability to bounce back—a trait that has taught me to be stubborn and slow to give up," he reflected.
Looking ahead, Dr. Pui remains focused on addressing remaining challenges in the field. His goals include finding effective treatments for the 10% of patients with refractory or relapsed ALL, developing affordable treatments for patients in developing countries, and replacing toxic chemotherapy with more targeted, less toxic alternatives to improve quality of life.
Through the Department of Global Pediatric Medicine at St. Jude, Dr. Pui continues to expand his impact, collaborating with colleagues worldwide to accelerate progress in pediatric cancer treatment. His work with the Ponte di Legno study group, bringing together 15 international study groups, and the annual St. Jude-VIVA Forum, which has educated hundreds of pediatric oncologists in Asia, exemplifies his commitment to global collaboration in advancing pediatric oncology.
